Brentuximab Vedotin in Early Stage Hodgkin Lymphoma (NCT04685616)
A Randomised Phase III Trial With a PET Response Adapted Design Comparing ABVD +/- ISRT With A2VD +/- ISRT in Patients With Previously Untreated Stage IA/IIA Hodgkin Lymphoma
🩺 Plain-English Summary (8th-Grade Level)
RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand. Trial 2 will be led by the Canadian Cancer Trials Group (CCTG) and conducted in North America, with CCTG the regulatory sponsor in Canada, and University of Miami the regulatory sponsor and IND holder in the US. Datasets from Trial 1 and Trial 2 will be combined to achieve the total sample size. Data analysis will be performed by UCL and therefore UCL is responsible for the clinicaltrials.gov entry. Eligible patients will be randomised to receive either ABVD or A2VD chemotherapy. An interim PET-CT scan will be performed after 2 cycles of treatment, which will be used to adapt subsequent treatment. Patients will receive a total of 3-4 cycles of chemotherapy and may also receive involved site radiotherapy as consolidation. Patients will be followed up for a minimum of 5 years after treatment.
Who can join: Review the eligibility criteria below.
Location: Stanford University - (Stanford Cancer Institute) — Stanford, California
Age range: 16 Years to 69 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (72 Sites)
Showing the first 25 of 72 sites.
- Stanford University - (Stanford Cancer Institute) — Stanford, California
- University of Miami School of Medicine — Miami, Florida
- Memorial Sloan Kettering Cancer Center — New York, New York
- Royal North Shore Hospital — Saint Leonards, New South Wales
- Townsville University Hospital — Townsville, Queensland
- Royal Adelaide Hospital — Adelaide,
- Box Hill Hospital — Box Hill,
- Royal Brisbane and Women's Hospital — Brisbane,
- Royal Darwin Hospital — Darwin,
- Liverpool Hospital — Liverpool,
- Sunshine Hospital (Western Health) — Melbourne,
- Concord Repatriation General Hospital — Sydney,
- St George Hospital — Sydney,
- AZ Delta Campus Rumbeke — Roeselare, West Flanders
- Universitair Ziekenhuis Antwerpen — Antwerp,
- Ziekenhuis Netwerk Antwerpen — Antwerp,
- UZ Leuven — Leuven,
- CHU-UCL Namur — Namur,
- QEII Health Sciences Centre — Halifax, Nova Scotia
- Juravinski Cancer Centre — Hamilton, Ontario
- Ottowa Hospital Research Institute — Ottawa,
- Saint John Regional Hospital — Saint John,
- University Health Network Princess Margaret Cancer Centre — Toronto,
- Vancouver Cancer Centre — Vancouver,
- CancerCare Manitoba — Winnipeg,
📞 Contact the Study Coordinator
Phone: +44(0)207 679 9860
Email: ctc.radar@ucl.ac.uk
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hodgkin Lymphoma
- Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma — Detroit, Michigan
- Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) — Birmingham, Alabama
- PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma — Houston, Texas
- Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma — Salt Lake City, Utah
- A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) — Detroit, Michigan
- Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL — Chicago, Illinois
Explore by condition: All Hodgkin Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.